AstraZeneca Pharma India Ltd. updates on NPPA overcharging demand and court stay
Astrazeneca Pharma India · Pharmaceuticals & Biotechnology
Key highlights
- NPPA issued a demand notice on July 27, 2026, for alleged overcharging on Betaloc-50 tablets
- Delhi High Court stayed the demand notice operation on August 24, 2026, until February 10, 2027
- Company deposited 15% of the demanded amount as directed by the court and is taking necessary steps
Why it's rated notable: The filing gives no amount for the Demand Notice, only that the High Court stayed it subject to a deposit of 15% of the unstated amount, so the level is kept at medium.
Original filing
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other order win filings this fortnight
- HLE Glascoat subsidiary Kinam Engineering secures $42-48M international order
- SpectraA Technology Solutions receives ₹21 crore domestic order for brewery project
- Ashoka Buildcon receives LoA for NHAI expressway project worth ₹865.90 crore
- L&T bags significant order from Noida Metro for Aqua Line Extension
- South West Pinnacle Exploration H1 FY27 revenue up 16% to Rs. 1194 Mn, PAT up 23%
- SEAMEC Limited awarded USD 26.14 million subsea installation contract by L&T
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.